NeoPhore Limited
NeoPhore Limited is a small molecule neoantigen immuno-oncology company developing a pipeline of drugs targeting proteins in the DNA mismatch repair pathway. Its first-in-class MMR inhibitors aim to increase immunogenicity in solid tumors, making them more responsive to immunotherapy. This approach seeks to improve clinical outcomes for cancer patients.
Buy Funded Startups lists
Funding Round: Series B
Funding Amount: $39.5M
Date: 01-Feb-2024
Investors: CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, NEVA SGR, LIFTT, Simon Fiduciaria
Markets: Biotechnology, Drug Discovery, Small Molecule Therapeutics, Oncology, Immuno-oncology, Cancer, Genetics, and Translational Medicine
HQ: Cambridge, Cambridgeshire, United Kingdom
Founded: 2017
Website: https://www.neophore.com/
LinkedIn: https://www.linkedin.com/company/neophore-ltd
Twitter: https://twitter.com/neophoreltd
Crunchbase: https://www.crunchbase.com/organization/neophore
Leave a Comment
Comments
No comments yet.